Skip to main content
Journal cover image

Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.

Publication ,  Journal Article
Ong, MS; Ringold, S; Kimura, Y; Schanberg, LE; Tomlinson, GA; Natter, MD; CARRA Registry Investigators,
Published in: Arthritis Rheumatol
October 2021

OBJECTIVE: To investigate the effects of early introduction of biologic disease-modifying antirheumatic drugs (bDMARDs) on the disease course in untreated polyarticular juvenile idiopathic arthritis (JIA). METHODS: We analyzed data on patients with polyarticular JIA participating in the Start Time Optimization of Biologics in Polyarticular JIA (STOP-JIA) study (n = 400) and a comparator cohort (n = 248) from the Childhood Arthritis and Rheumatology Research Alliance Registry. Latent class trajectory modeling (LCTM) was applied to identify subgroups of patients with distinct disease courses based on disease activity (clinical Juvenile Arthritis Disease Activity Score in 10 joints) over 12 months from baseline. RESULTS: In the STOP-JIA study, 198 subjects (49.5%) received bDMARDs within 3 months of baseline assessment. LCTM analyses generated 3 latent classes representing 3 distinct disease trajectories, characterized by slow, moderate, or rapid disease activity improvement over time. Subjects in the rapid improvement trajectory attained inactive disease within 6 months from baseline. Odds of being in the rapid improvement trajectory versus the slow improvement trajectory were 3.6 times as high (95% confidence interval 1.32-10.0; P = 0.013) for those treated with bDMARDs ≤3 months from baseline compared with subjects who started bDMARDs >3 months after baseline, after adjusting for demographic characteristics, clinical attributes, and baseline disease activity. Shorter disease duration at first rheumatology visit approached statistical significance as a predictor of favorable trajectory without bDMARD treatment. CONCLUSION: Starting bDMARDs within 3 months of baseline assessment is associated with more rapid achievement of inactive disease in subjects with untreated polyarticular JIA. These results demonstrate the utility of trajectory analysis of disease course as a method for determining treatment efficacy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Arthritis Rheumatol

DOI

EISSN

2326-5205

Publication Date

October 2021

Volume

73

Issue

10

Start / End Page

1910 / 1920

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Male
  • Humans
  • Female
  • Disease Progression
  • Consensus
  • Child
  • Biological Products
  • Arthritis, Juvenile
  • Antirheumatic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ong, M. S., Ringold, S., Kimura, Y., Schanberg, L. E., Tomlinson, G. A., Natter, M. D., & CARRA Registry Investigators, . (2021). Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis Rheumatol, 73(10), 1910–1920. https://doi.org/10.1002/art.41892
Ong, Mei Sing, Sarah Ringold, Yukiko Kimura, Laura E. Schanberg, George A. Tomlinson, Marc D. Natter, and Marc D. CARRA Registry Investigators. “Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.Arthritis Rheumatol 73, no. 10 (October 2021): 1910–20. https://doi.org/10.1002/art.41892.
Journal cover image

Published In

Arthritis Rheumatol

DOI

EISSN

2326-5205

Publication Date

October 2021

Volume

73

Issue

10

Start / End Page

1910 / 1920

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Male
  • Humans
  • Female
  • Disease Progression
  • Consensus
  • Child
  • Biological Products
  • Arthritis, Juvenile
  • Antirheumatic Agents